Market News
Stay updated with the latest market trends, earnings, and economic indicators.

Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 23 June 2026 - Mint
Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 23 June 2026Mint
HDFC MF, ADIA among buyers as Sepia Investments offloads Rs 749 crore in Corona Remedies via block deal
Sepia Investments and Anchor Partners sold shares worth about Rs 777 crore in Corona Remedies through block deals. HDFC Mutual Fund emerged as the largest buyer, while several institutional investors, including Aberdeen entities, ADIA, Invesco and WhiteOak, also accumulated stakes.
Nifty trades above 23,950 mark; European market advance
IT, media and realty shares advanced while metal, PSU Bank and pharma shares declined.
Nifty trades above 23,950 mark; European market advanced
IT, media and realty shares advanced while metal, PSU Bank and pharma shares declined.

Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 16 June 2026
Shares to buy or sell: Chandan Taparia has recommended three stocks to buy today, 16 June 2026 - Bharat Forge, BSE and The Phoenix Mills shares.
Nifty ends above 23,850 mark; broader mrkt outperforms
Realty, consumer durables and auto shares advanced while pharma and media shares declined.

Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 12 June 2026 - Mint
Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 12 June 2026Mint

Glenmark Pharma Profit Expected To Soar 5x in Two Years, Says Motilal Oswal — Check Target Price
Glenmark Pharma's shares are likely to remain in focus after Motilal Oswal has reiterated its positive stance on the stock.

ICICI Lombard: AI Integration Lifts Growth Outlook — Buy, Sell or Hold? Read Motilal Oswal's Analysis
Leadership in motor insurance, accelerating momentum in retail health, expanding distribution capabilities, growing AI integration and a strong balance sheet remains ICICI Lombard's key growth drivers.
PE investor BC Investments sells Rs 612 crore stake in Emcure Pharma; Kotak MF picks up stake
Private equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per share. Despite this divestment, analysts remain positive on Emcure's growth outlook across its core therapeutic segments.
Sebi may widen 50% overlap rule to thematic passive mutual fund schemes
Curb on number of smart-beta schemes also likely; move aimed at curbing proliferation in segment

Ajanta Pharma promoter sells ₹1,024 crore stake; mutual funds step in as buyers
A promoter entity of Ajanta Pharma has sold a 2.8% stake in the drugmaker for over ₹1,000 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund emerging as the key buyers.